M
Martin Moik
Researcher at Paracelsus Private Medical University of Salzburg
Publications - 11
Citations - 449
Martin Moik is an academic researcher from Paracelsus Private Medical University of Salzburg. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 8, co-authored 11 publications receiving 399 citations.
Papers
More filters
Journal ArticleDOI
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
Michael Gnant,Brigitte Mlineritsch,Herbert Stoeger,G. Luschin-Ebengreuth,Michael Knauer,Martin Moik,Raimund Jakesz,Michael Seifert,Susanne Taucher,Vesna Bjelic-Radisic,Marija Balic,Holger Eidtmann,Wolfgang Eiermann,Günther G. Steger,Werner Kwasny,Peter Dubsky,U Selim,Florian Fitzal,Gerhard Hochreiner,Viktor Wette,Paul Sevelda,Ferdinand Ploner,Rupert Bartsch,Christian Fesl,Richard Greil +24 more
TL;DR: The final results from ABCSG 12 suggest that twice-yearly ZOL enhances the efficacy of adjuvant endocrine treatment, and this benefit is maintained long-term.
Journal ArticleDOI
Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study
R. Greil,Martin Moik,Roland Reitsamer,S. Ressler,M. Stoll,K. Namberger,Christian Menzel,B. Mlineritsch +7 more
TL;DR: The 22% pCR rate in a HER2-negative population suggests that addition of bevacizumab increases the activity of neoadjuvant capecitabine-docetaxel, and further evaluation of this regimen in early breast cancer is recommended.
Proceedings ArticleDOI
Abstract GS3-01: A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial
M. Gnant,Günther G. Steger,Richard Greil,Florian Fitzal,Brigitte Mlineritsch,D Manfreda,Christoph Tausch,Marija Balic,P Dubsky,Martin Moik,Josef Thaler,Daniel Egle,Vesna Bjelic-Radisic,U Selim,Ruth Exner,Christian F. Singer,E. Melbinger-Zeinitzer,Ferdinand Haslbauer,Herbert Stöger,R Helfgott,P. Sevelda,H. Trapl,Viktor Wette,L. Sölkner,Raimund Jakesz +24 more
TL;DR: After 5 years of adjuvant endocrine therapy (Tamoxifen or AI or Sequence), 2 additional years of Anastrozole are sufficient for extended adjuant therapy – a further extension to 5 additional years did not yield additional outcome benefit but added toxicity.
Journal ArticleDOI
A modified Phenol-chloroform extraction method for isolating circulating cell free DNA of tumor patients
TL;DR: A modified phenol/chloroform extraction method for the isolation of cfDNA is evaluated and compared it with published standard methods for cfDNA isolation.
Journal ArticleDOI
Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial
Georg Pfeiler,Herbert Stöger,Peter Dubsky,B. Mlineritsch,Christian F. Singer,Marija Balic,Florian Fitzal,Martin Moik,Werner Kwasny,U Selim,K Renner,Ferdinand Ploner,Günther G. Steger,Michael Seifert,Friedrich Hofbauer,P. Sandbichler,Hellmut Samonigg,Raimund Jakesz,Richard Greil,Christian Fesl,Michael Gnant +20 more
TL;DR: Overweight+obese patients had an increased risk for distant recurrences and a worse overall survival compared with normal weight patients and patients treated with the combination of tamoxifen plus aminoglutethimide.